Discordance between biochemical markers of liver activity and fibrosis (Actitest®-Fibrotest®) and liver biopsy in patients with chronic hepatitis C

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 10, 2008, Pages 858-865

  Fontanges, T ^a   Bailly, F ^b   Trepo, E ^c   Chevallier, M ^d   Maynard Muet, M ^b   Nalet, B ^a   Beorchia, S ^e   Pillon, D ^f   Moindrot, H ^g   Froissart, B ^h   Slaoui, M ^e   Tinel, X ^a   Pradat, P ^b   Trepo, C ^b  

^a Centre hospitalier général   (France)

^b HÔTEL DIEU   (France)

^c Laboratoire d'analyse de biologie médicale   (France)

^d Service d'Anatomie Pathologique   (France)

^e Cabinet de gastro entérologie et hépatologie   (France)

^f Centre Hospitalier Général   (France)

^g CENTRE HOSPITALIER DE VALENCE   (France)

^h Cabinet de Gastro Entérologie et Hépatologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHRONIC HEPATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; NONHUMAN; VIRUS HEPATITIS; VIRUS LOAD;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 54049117708     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2008.05.019     Document Type: Article

References (23)

1. A.N.A.E.S. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002; 26 Spec No 2: B303-B320.
2. Cadranel J.F., Rufat P., Degos F., and For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 32 (2000) 477-481
3. Adams L.A., Bulsara M., Rossi E., DeBoer B., Speers D., George J., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51 (2005) 1867-1873
4. Calès P., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet M.C., Konate A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 (2005) 1373-1381
5. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
6. Leroy V., Monier F., Bottari S., Trocme C., Sturm N., Hilleret M.N., et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99 (2004) 271-279
7. Patel K., Gordon S.C., Jacobson I., Hezode C., Oh E., Smith K.M., et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 41 (2004) 935-942
8. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127 (2004) 1704-1713
9. Sud A., Hui J.M., Farrell G.C., Bandara P., Kench J.G., Fung C., et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 39 (2004) 1239-1247
10. Bourliere M., Penaranda G., Renou C., Botta-Fridlund D., Tran A., Portal I., et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 13 (2006) 659-670
11. Imbert-Bismut F., Messous D., Thibault V., Myers R.B., Piton A., Thabut D., et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 42 (2004) 323-333
12. Poynard T., Imbert-Bismut F., Ratziu V., Chevret S., Jardel C., Moussalli J., et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 9 (2002) 128-133
13. Poynard T., Munteanu M., Ngo Y., Torres M., Benhamou Y., Thabut D., et al. Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology 43 (2006) 374-375
14. Poynard T., Halfon P., Castera L., Charlotte F., Le Bail B., Munteanu M., et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 25 (2007) 733-739
15. Fontaine H., Petitprez K., Roudot-Thoraval F., and Trinchet J.C. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 31 (2007) 504-509
16. Halfon P., Bourliere M., Deydier R., Botta-Fridlund D., Renou C., Tran A., et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 101 (2006) 547-555
17. Poynard T., Munteanu M., Imbert-Bismut F., Charlotte F., Thabut D., Le Calvez S., et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 50 (2004) 1344-1355
18. Bedossa P., Poynard T., and The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24 (1996) 289-293
19. Halfon P., Bacq Y., De Muret A., Penaranda G., Bourliere M., Ouzan D., et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 46 (2007) 395-402
20. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
21. Oberti F., Valsesia E., Pilette C., Rousselet M.C., Bedossa P., Aube C., et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 113 (1997) 1609-1616
22. Pilette C., Rousselet M.C., Bedossa P., Chappard D., Oberti F., Rifflet H., et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 28 (1998) 439-446
23. Rousselet M.C., Michalak S., Dupre F., Croue A., Bedossa P., Saint-Andre J.P., et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 41 (2005) 257-264